Stockscreener 앱 받기
34.11
3.23%
-1.14
시간 외 거래:
34.11
전일 마감가:
$35.25
열려 있는:
$35.85
하루 거래량:
2.10M
Relative Volume:
1.35
시가총액:
$4.07B
수익:
$18.47M
순이익/손실:
$-589.53M
주가수익비율:
-6.4848
EPS:
-5.26
순현금흐름:
$-399.80M
1주 성능:
-7.03%
1개월 성능:
-0.41%
6개월 성능:
-20.23%
1년 성능:
-36.83%
1일 변동 폭
$33.63
$36.79
1주일 범위
$33.63
$36.79
52주 변동 폭
$29.31
$59.39
Cytokinetics Inc Stock (CYTK) Company Profile
명칭
Cytokinetics Inc
전화
(650) 624-3000
주소
350 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA
CYTK을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CYTK
Cytokinetics Inc
|
34.11 | 4.20B | 18.47M | -589.53M | -399.80M | -5.26 |
|
VRTX
Vertex Pharmaceuticals Inc
|
366.54 | 98.88B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.00 | 58.84B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
438.93 | 56.12B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
661.83 | 41.20B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.18 | 35.49B | 3.81B | -644.79M | -669.77M | -6.24 |
Cytokinetics Inc Stock (CYTK) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-30 | 재개 | Raymond James | Mkt Perform |
| 2025-04-24 | 개시 | Barclays | Overweight |
| 2025-02-07 | 개시 | Citigroup | Buy |
| 2025-01-22 | 개시 | Stifel | Buy |
| 2024-11-08 | 개시 | RBC Capital Mkts | Outperform |
| 2024-08-13 | 다운그레이드 | Goldman | Buy → Neutral |
| 2024-01-24 | 다운그레이드 | UBS | Buy → Neutral |
| 2024-01-05 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2023-11-09 | 개시 | Goldman | Buy |
| 2023-11-07 | 개시 | B. Riley Securities | Buy |
| 2023-08-15 | 개시 | SVB Securities | Outperform |
| 2023-02-17 | 개시 | BofA Securities | Neutral |
| 2022-12-23 | 재확인 | Needham | Buy |
| 2022-12-20 | 개시 | Truist | Buy |
| 2022-10-11 | 개시 | UBS | Buy |
| 2022-01-28 | 개시 | Goldman | Buy |
| 2021-12-22 | 개시 | Oppenheimer | Outperform |
| 2021-12-10 | 개시 | JP Morgan | Overweight |
| 2021-10-07 | 개시 | Jefferies | Buy |
| 2021-03-12 | 개시 | Wolfe Research | Outperform |
| 2021-02-18 | 개시 | Barclays | Overweight |
| 2021-01-20 | 재확인 | H.C. Wainwright | Buy |
| 2020-10-29 | 개시 | Goldman | Neutral |
| 2020-07-10 | 개시 | Raymond James | Strong Buy |
| 2020-05-05 | 개시 | Mizuho | Buy |
| 2020-04-09 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2018-09-21 | 개시 | Cantor Fitzgerald | Overweight |
| 2018-09-10 | 재개 | Morgan Stanley | Equal-Weight |
| 2017-11-22 | 재확인 | Morgan Stanley | Overweight |
| 2017-11-22 | 다운그레이드 | Needham | Strong Buy → Buy |
| 2017-11-21 | 재확인 | H.C. Wainwright | Buy |
| 2017-07-31 | 개시 | Morgan Stanley | Overweight |
| 2017-03-08 | 개시 | Rodman & Renshaw | Buy |
| 2017-02-06 | 업그레이드 | Needham | Buy → Strong Buy |
| 2016-12-16 | 개시 | Cantor Fitzgerald | Overweight |
| 2016-07-28 | 재확인 | Needham | Buy |
| 2015-11-10 | 재확인 | FBR Capital | Outperform |
| 2015-11-09 | 재확인 | ROTH Capital | Buy |
| 2015-07-24 | 재확인 | MLV & Co | Buy |
| 2014-12-31 | 재확인 | ROTH Capital | Buy |
| 2014-11-04 | 업그레이드 | MLV & Co | Hold → Buy |
| 2014-04-28 | 재확인 | Needham | Buy |
모두보기
Cytokinetics Inc 주식(CYTK)의 최신 뉴스
Is Cytokinetics Incorporated stock entering bullish territoryPrice Movement and Market Sentiment Analysis - Newser
Using Ichimoku Cloud for Cytokinetics Incorporated technicalsSafe Momentum Strategy With Trend Analysis - Newser
Citigroup Issues Pessimistic Forecast for Cytokinetics (NASDAQ:CYTK) Stock Price - Defense World
Cytokinetics (NASDAQ:CYTK) Upgraded by Wall Street Zen to “Hold” Rating - Defense World
Cytokinetics and the Imminent Commercialization of Aficamten: A High-Conviction Buy Before the December 2025 FDA Decision - AInvest
Cytokinetics and the Aficamten Opportunity: Navigating FDA Delays, Strong Analyst Consensus, and High GF Value for a High-Probability Breakout in 2026 - AInvest
Cytokinetics Second Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Pattern recognition hints at Cytokinetics Incorporated upsideTechnical Safety Zone Pattern Recognition - Newser
What candlestick patterns are forming on Cytokinetics IncorporatedFree High Yield Stock Screening Results - Newser
What indicators show strength in Cytokinetics IncorporatedFree Pattern Breakout Entry Stock Forecast - Newser
Cytokinetics 2025 Q2 Earnings Narrowed Losses Amid Revenue Surge - AInvest
Cytokinetics: Citigroup maintains Buy rating, lowers PT to $77 from $80. - AInvest
Cytokinetics shares rise 3.20% after-hours following Q2 2025 earnings call. - AInvest
Cytokinetics, Incorporated shares fall 1.56% intraday after reporting earnings and regulatory updates. - AInvest
CYTK ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Cytokinetics, Incorporated - ACCESS Newswire
Cytokinetics rises as investors await US approval for heart drug - TradingView
Earnings call transcript: Cytokinetics Q2 2025 sees strong revenue beat - Investing.com
Earnings call transcript: Cytokinetics Q2 2025 sees strong revenue beat By Investing.com - Investing.com Australia
Navigating Financial Challenges Amid Promising Clinical Developments: Cytokinetics Inc. (CYTK) Q2 2025 Earnings Call Highlights - AInvest
Cytokinetics Q2 Loss Narrows, Revenue Rises - MarketScreener
Cytokinetics Q2 2025 Earnings Call Transcript - MarketBeat
Cytokinetics Reports Q2 2025 Financial Results and Updates - TipRanks
Cytokinetics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Cytokinetics shares rise on strong Q2 results By Investing.com - Investing.com Nigeria
Cytokinetics (CYTK) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance
Cytokinetics: Q2 Earnings Snapshot - San Francisco Chronicle
CYTOKINETICS INC SEC 10-Q Report - TradingView
Cytokinetics Inc earnings beat by $0.30, revenue topped estimates - Investing.com Australia
Cytokinetics Earnings Surge: Revenue Jumps to $66.8M with FDA Decision on Key Drug Coming December - Stock Titan
ATTENTION Cytokinetics, Incorporated Investors: You May Have Been Affected by FraudContact Levi & Korsinsky to Discuss Your Rights - ACCESS Newswire
Federated Hermes Inc. Has $1.37 Million Holdings in Cytokinetics, Incorporated (NASDAQ:CYTK) - Defense World
TR | OpenAI4o Initiates Cytokinetics(CYTK.US) With Hold Rating, Announces Target Price $37 - 富途牛牛
Top Executive Sells Thousands in Cytokinetics Stock! - TipRanks
Malik, Cytokinetics EVP, sells $72,680 in shares By Investing.com - Investing.com Canada
Malik, Cytokinetics EVP, sells $72,680 in shares - Investing.com
Cytokinetics EVP Research & Development Malik Fady Ibraham Buys 2000 Shares at $10.6/Share, Sells 2000 Shares at $36.34/Share. - AInvest
Spinal Muscular Atrophy Market Opportunities and Future Scope - openPR.com
Cytokinetics, Incorporated (NASDAQ:CYTK) Shares Purchased by Assetmark Inc. - Defense World
Published on: 2025-08-04 22:46:47 - metal.it
Cytokinetics Incorporated Price Holds Above Key Fib LevelAI Forecast for Trending Stocks Indicates Upside - beatles.ru
Why Cytokinetics Incorporated stock attracts strong analyst attentionSwing Entry Risk Mitigation with Chart Analysis - Newser
What are analysts’ price targets for Cytokinetics Incorporated in the next 12 monthsOutstanding capital growth - Jammu Links News
How strong is Cytokinetics Incorporated company’s balance sheetBuild a diversified portfolio for risk management - Jammu Links News
Cytokinetics Incorporated Stock Analysis and ForecastBuild wealth with long-term growth strategies - Jammu Links News
What makes Cytokinetics Incorporated stock price move sharplyCapitalize on emerging industry trends - Jammu Links News
What is Cytokinetics Incorporated company’s growth strategyMarket-leading capital gains - Jammu Links News
Cytokinetics (NASDAQ:CYTK) Coverage Initiated by Analysts at Raymond James Financial - MarketBeat
What catalysts could drive Cytokinetics Incorporated stock higher in 2025Build a winning investment portfolio - Jammu Links News
Should I hold or sell Cytokinetics Incorporated stock in 2025Rapid growth opportunities - Jammu Links News
What are the latest earnings results for Cytokinetics IncorporatedExpert Picks Outlook For Beginners - jammulinksnews.com
Watch for Trend Continuation in Cytokinetics Incorporated Next WeekSwing Trading Plan With Smart Signals in Review - beatles.ru
Cytokinetics Inc (CYTK) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.24%
3.39%
자본화:
|
볼륨(24시간):